113P Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on durvalumab eligibility and safety profile

Cortiula, Francesco; Ruysscher, Dirk De; Dursun, Safiye; Steens, M.; Bootsma, G.; Canters, R.; Rinaldi, I.; Taasti, V.; Houben, Rik; Reynders, Kobe; Peeters, Stéphanie; Angrisani, Antonio; Hattu, D.; Hendriks, L.

doi:10.1016/j.annonc.2022.02.140

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidences of immunotherapy-related adverse events of any grade in the IMRT and IMPT groups were 21.4% and 30.8% (P = 0.062), and the incidences of pneumonia during immunotherapy were 25% and 23% (P = 0.8), respectively; safety was similar in both groups. Patient performance status scores after cCRT were significantly better in the IMPT group than in the IMRT group (performance status ≤ 1: 92.9% vs. 71.8%, P < 0.032) [102]. Preclinical evidence suggests that high-dose, low-segmentation radiotherapy enhances antitumor immunity and leads to significant tumor control blockade when used in combination with ICIs [103].…”

Section: Improvements In Radiotherapy Techniques For the Treatment Of...mentioning

confidence: 94%

“…Patient performance status scores after cCRT were significantly better in the IMPT group than in the IMRT group (performance status ≤ 1: 92.9% vs . 71.8%, P < 0.032) [ 102 ]. Preclinical evidence suggests that high‐dose, low‐segmentation radiotherapy enhances antitumor immunity and leads to significant tumor control blockade when used in combination with ICIs [ 103 ].…”

Section: Unresectable La‐nsclcmentioning

confidence: 99%

See 1 more Smart Citation

Management of locally advanced non‐small cell lung cancer: State of the art and future directions

Miao,

Zhao,

Han

et al. 2023

Cancer Communications

View full text Add to dashboard Cite

Lung cancer is the second most common and the deadliest type of cancer worldwide. Clinically, non‐small cell lung cancer (NSCLC) is the most common pathological type of lung cancer; approximately one‐third of affected patients have locally advanced NSCLC (LA‐NSCLC, stage III NSCLC) at diagnosis. Because of its heterogeneity, LA‐NSCLC often requires multidisciplinary assessment. Moreover, the prognosis of affected patients is much below satisfaction, and the efficacy of traditional therapeutic strategies has reached a plateau. With the emergence of targeted therapies and immunotherapies, as well as the continuous development of novel radiotherapies, we have entered an era of novel treatment paradigm for LA‐NSCLC. Here, we reviewed the landscape of relevant therapeutic modalities, including adjuvant, neoadjuvant, and perioperative targeted and immune strategies in patients with resectable LA‐NSCLC with/without oncogenic alterations; as well as novel combinations of chemoradiation and immunotherapy/targeted therapy in unresectable LA‐NSCLC. We addressed the unresolved challenges that remain in the field, and examined future directions to optimize clinical management and increase the cure rate of LA‐NSCLC.

show abstract

Section: Improvements In Radiotherapy Techniques For the Treatment Of...mentioning

confidence: 94%

Section: Unresectable La‐nsclcmentioning

confidence: 99%

Management of locally advanced non‐small cell lung cancer: State of the art and future directions

Miao,

Zhao,

Han

et al. 2023

Cancer Communications

View full text Add to dashboard Cite

show abstract

113P Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on durvalumab eligibility and safety profile

Cited by 1 publication

References 0 publications

Management of locally advanced non‐small cell lung cancer: State of the art and future directions

Management of locally advanced non‐small cell lung cancer: State of the art and future directions

Contact Info

Product

Resources

About